CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
bevacizumab [Avastin] +2 moredrug
Likely dose
bevacizumab [Avastin] 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02005549
NCT02005549Phase 2Completed
CompareCT.gov

A Phase II Study of Bevacizumab With Docetaxel and Capecitabine in the Neoadjuvant Setting for Breast Cancer Patients

Hoffmann-La Roche·interventional·Posted Dec 9, 2013·Updated Jul 14, 2014

In Brief

A Phase 2 clinical trial evaluating bevacizumab [Avastin], docetaxel, and 1 other intervention for Breast Cancer. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer. Avastin will be administered every 3 weeks, for the first 5 cycles of chemotherapy. The anticipated time on study treatment is 3-12 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesAustria
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 9, 2013
Enrollment StartFeb 1, 2006
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.6 years ago

Interventions

bevacizumab [Avastin]drug

15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles

docetaxeldrug

75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles

capecitabine [Xeloda]drug

950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks